Neuronet is a three-year Coordination and Support Action that kicked off in March 2019. The aim of Neuronet is to set up an efficient platform to boost collaboration across research projects focusing on neurodegenerative diseases, including but not limited to Alzheimer’s disease. These projects have all been launched by the world’s biggest public-private partnership in the life sciences, the Innovative Medicines Initiative (IMI). Neuronet aims to assist in identifying gaps in research, multiply the impact of findings and enhance project visibility, whilst also facilitating connections with related initiatives in Europe and worldwide. Neuronet has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA and Parkinson’s UK.
Health, Public-Private Partnership, Innovative Medicines Initiative, Neurodegeneration research, Alzheimer's disease, Parkinson's disease